Although many studies have demonstrated a role for substance P in pain, there have been conflicting reports implicating the involvement of substance P in neuropathic pain models. In this study, the non-peptide neurokinin-1 (NK-1) receptor antagonist, L-732,138 was chronically administered by intrathecal (i.t.) injection to rats with mono-neuropathy produced by sciatic nerve constriction. Rats exhibited tactile allodynia and cold hyperalgesia over a 16-day testing period. L-732,138 (5-200 nmol) administered i.t. prior to and for 3 consecutive days post-surgery attenuated the mechanical allodynia and cold hyperalgesia on days 4 and 8 post-surgery. The effects of i.t. L-732,138 were also determined in rats with established nerve injury-induced neuropathy. The NK-1 receptor antagonist was injected for 4 consecutive days starting on day 8 post-sciatic nerve injury. Administration of L-732,138 (5-200 nmol) i.t. produced both anti-allodynic and anti-hyperalgesic effects on day 12, but the effect was not permanent, as nociceptive thresholds were similar to controls by day 16. These results demonstrate that substance P is involved both in the induction and the maintenance of neuropathic pain and provides justification for the development and administration of substance P antagonists for the management of clinical neuropathic pain.
Introduction
Neuropathic pain resulting from nerve injury is a persistent condition characterized by spontaneous pain, allodynia (nociceptive responses to normally innocuous stimuli), and hyperalgesia (increased sensitivity and exaggerated responses to nociceptive stimuli). Although patients sometimes find pain relief with conventional analgesics such as opioids, neuropathic pain is typically poorly managed (Arnér and Meyerson, 1988; Max et al., 1988; Kupers et al., 1991) . Moreover, the use of current therapies such as tricyclic anti-depressants is not always well tolerated or adequately effective (McQuay et al., 1996) . The development of animal neuropathic pain models has greatly advanced our understanding of the pathophysiology and mechanisms of neuropathic pain states (Bennett and Xie, 1988; Kim and Chung, 1992; Seltzer et al., 1990 ). One valid model indicative of neuropathic pain is produced by chronic constriction of the rat sciatic nerve with polyethylene tubing (cuff) (Mosconi and Kruger, 1996) . This model induces behavioral characteristics analogous to the model described by Bennett and Xie (1988) , including thermal hyperalgesia as well as tactile allodynia, however, the behavioral manifestations produced by the cuff are reportedly less variable (Mosconi and Kruger, 1996) .
Injury to a peripheral nerve produces altered peptide expression within the spinal cord and dorsal root ganglia (DRG). Following sciatic nerve injury, many neurochemical changes occur. Accordingly, these changes may include a decrease in the levels of substance P and calcitonin gene related peptide (CGRP), as well as increases in vasoactive intestinal peptide, galanin, neuropepide Y, and cholecystokinin (CCK) over various times after nerve injury (reviewed by Wiesenfeld-Hallin and Xu, 1996) . It has been suggested that alterations in peptide expression may represent adaptive responses that promote survival and recovery of damaged neurons (Hökfelt et al., 1994) . However, these changes also may be responsible for 
